- Home
- WNS vs MIRM Comparison
WNS vs MIRM Comparison
Compare WNS & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNS
- MIRM
- Stock Information
- Founded
- WNS 1996
- MIRM 2018
- Country
- WNS India
- MIRM United States
- Employees
- WNS N/A
- MIRM N/A
- Industry
- WNS Business Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- WNS Consumer Discretionary
- MIRM Health Care
- Exchange
- WNS Nasdaq
- MIRM Nasdaq
- Market Cap
- WNS 2.1B
- MIRM 1.9B
- IPO Year
- WNS N/A
- MIRM 2019
- Fundamental
- Price
- WNS $50.50
- MIRM $44.50
- Analyst Decision
- WNS Buy
- MIRM Strong Buy
- Analyst Count
- WNS 7
- MIRM 13
- Target Price
- WNS $60.43
- MIRM $57.00
- AVG Volume (30 Days)
- WNS 578.2K
- MIRM 356.8K
- Earning Date
- WNS 10-17-2024
- MIRM 11-12-2024
- Dividend Yield
- WNS N/A
- MIRM N/A
- EPS Growth
- WNS N/A
- MIRM N/A
- EPS
- WNS 2.50
- MIRM N/A
- Revenue
- WNS $1,308,696,000.00
- MIRM $307,028,000.00
- Revenue This Year
- WNS N/A
- MIRM $73.07
- Revenue Next Year
- WNS $7.96
- MIRM $27.98
- P/E Ratio
- WNS $20.22
- MIRM N/A
- Revenue Growth
- WNS 2.07
- MIRM 112.14
- 52 Week Low
- WNS $39.85
- MIRM $23.14
- 52 Week High
- WNS $72.57
- MIRM $48.89
- Technical
- Relative Strength Index (RSI)
- WNS 48.97
- MIRM 65.32
- Support Level
- WNS $50.16
- MIRM $41.09
- Resistance Level
- WNS $55.86
- MIRM $48.89
- Average True Range (ATR)
- WNS 1.80
- MIRM 2.16
- MACD
- WNS 0.41
- MIRM 0.57
- Stochastic Oscillator
- WNS 42.74
- MIRM 59.09
About WNS WNS (Holdings) Limited Sponsored ADR (Jersey)
WNS (Holdings) Ltd is a Global provider of business process management (BPM) services, offering comprehensive data, voice, analytical, and business transformation services with a blended onshore, nearshore and offshore delivery model. The company's segment includes Banking/Financial Services, and Insurance; Travel, Shipping/Logistics, and Utilities; Manufacturing/Retail/Consumer, Hi-tech/Professional Services, and Procurement; Healthcare/Life Sciences. Geographically the company generates the majority of its revenue from North America (primarily the US), followed by the UK. The company also has a presence in Australia, Europe (excluding the UK), and South Africa.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.